Ready-to-use nanopore platform for label-free small molecule quantification: Ethanolamine as first example.

Aptamer Ethanolamine Label-free detection Nanopore Small molecules

Journal

Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 19 06 2023
revised: 06 10 2023
accepted: 26 10 2023
pubmed: 26 11 2023
medline: 26 11 2023
entrez: 25 11 2023
Statut: ppublish

Résumé

In recent decades, nanopores have become a promising diagnostic tool. Protein and solid-state nanopores are increasingly used for both RNA/DNA sequencing and small molecule detection. The latter is of great importance, as their detection is difficult or expensive using available methods such as HPLC or LC-MS. DNA aptamers are an excellent detection element for sensitive and specific detection of small molecules. Herein, a method for quantifying small molecules using a ready-to-use sequencing platform is described. Taking ethanolamine as an example, a strand displacement assay is developed in which the target-binding aptamer is displaced from the surface of magnetic particles by ethanolamine. Non-displaced aptamer and thus the ethanolamine concentration are detected by the nanopore system and can be quantified in the micromolar range using our in-house developed analysis software. This method is thus the first to describe a label-free approach for the detection of small molecules in a protein nanopore system.

Identifiants

pubmed: 38007066
pii: S1549-9634(23)00075-8
doi: 10.1016/j.nano.2023.102724
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102724

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no competing interests.

Auteurs

Isabel Quint (I)

Institute of Precision Medicine, Furtwangen University, Jakob-Kienzle-Strasse 17, Villingen-Schwenningen 78054, Germany; Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard-Karls-University Tuebingen, Auf der Morgenstelle 8, Tuebingen 72076, Germany.

Jonathan Simantzik (J)

Institute of Precision Medicine, Furtwangen University, Jakob-Kienzle-Strasse 17, Villingen-Schwenningen 78054, Germany.

Lars Kaiser (L)

Institute of Precision Medicine, Furtwangen University, Jakob-Kienzle-Strasse 17, Villingen-Schwenningen 78054, Germany.

Stefan Laufer (S)

Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard-Karls-University Tuebingen, Auf der Morgenstelle 8, Tuebingen 72076, Germany; Tuebingen Center for Academic Drug Discovery & Development (TüCAD2), 72076 Tuebingen, Germany.

Rene' Csuk (R)

Institute of Organic Chemistry, Martin-Luther University Halle-Wittenberg, Kurt-Mothes-Str. 2, 06120 Halle (Saale), Germany.

David Smith (D)

Fraunhofer Institute IZI (Leipzig), Perlickstrasse 1, 04103 Leipzig, Germany.

Matthias Kohl (M)

Institute of Precision Medicine, Furtwangen University, Jakob-Kienzle-Strasse 17, Villingen-Schwenningen 78054, Germany. Electronic address: Matthias.Kohl@hs-furtwangen.de.

Hans-Peter Deigner (HP)

Institute of Precision Medicine, Furtwangen University, Jakob-Kienzle-Strasse 17, Villingen-Schwenningen 78054, Germany; EXIM Department, Fraunhofer Institute IZI (Leipzig), Schillingallee 68, 18057 Rostock, Germany; Faculty of Science, Eberhard-Karls-University Tuebingen, Auf der Morgenstelle 8, Tuebingen, 72076, Germany. Electronic address: hans-peter.deigner@hfu.eu.

Classifications MeSH